In this article SUNPHARMA-IN Follow your favorite stocks CREATE FREE ACCOUNT SHANGHAI, CHINA - NOVEMBER 05: People visit the booth of Organon during the 7th China International Import Expo (CIIE) at the National Exhibition and Convention Center (Shanghai) on November 5, 2024 in Shanghai, China. The 7th China International Import Expo (CIIE) kicked off in Shanghai on November 5. (Photo by Tang Yanj...
In this article SUNPHARMA-IN Follow your favorite stocks CREATE FREE ACCOUNT SHANGHAI, CHINA - NOVEMBER 05: People visit the booth of Organon during the 7th China International Import Expo (CIIE) at the National Exhibition and Convention Center (Shanghai) on November 5, 2024 in Shanghai, China. The 7th China International Import Expo (CIIE) kicked off in Shanghai on November 5. (Photo by Tang Yanjun/China News Service/VCG via Getty Images) China News Service | China News Service | Getty Images India's Sun Pharmaceutical Industries will acquire New Jersey-based Organon & Co in an all-cash deal that values the U.S. company at $11.75 billion, including debt. The Indian generic drugmaker will acquire all outstanding shares of Organon for $14 apiece, according to an exchange filing Monday by Sun Pharmaceutical . "Following a comprehensive review of strategic alternatives, our Board determined that this all‑cash transaction offers compelling and immediate value to Organon stockholders," said Carrie Cox, executive chair at Organon, in the joint statement. Organon , which was spun off from Merck in 2021, specializes in women's health and biosimilars and has more than 70 products that are sold across 140 countries. The acquisition will help lift Sun Pharma, India's largest drugmaker, into the top 25 global pharmaceutical companies, with a revenue of $12.4 billion, according to the press statement. "This transaction is a logical next step in strengthening Sun Pharma's global business," said Kirti Ganorkar, managing director at Sun Pharma. Organon's buyout will help the Indian company scale its medicine products, as the U.S. is a key market. The Organon buyout is part of Sun Pharmaceutical's strategy "of growing its Innovative Medicines business," the Indian company said in a statement. As per the European Medicines Agency, an innovative medicine contains an active substance or a combination of active substances that has not been authorized before. Sun Pharma innovative medic...
stanciuc/iStock via Getty Images The Janus Henderson Mortgage-Backed Securities ETF ( JMBS ) is an actively managed ETF focusing on high-quality agency MBS with moderate duration. JMBS's high-quality portfolio and above-average 5.5% dividend yield make the fund a buy. JMBS - Overview and Analysis Strategy and Portfolio JMBS focuses on high-quality agency MBS, with smaller allocations to other type...
stanciuc/iStock via Getty Images The Janus Henderson Mortgage-Backed Securities ETF ( JMBS ) is an actively managed ETF focusing on high-quality agency MBS with moderate duration. JMBS's high-quality portfolio and above-average 5.5% dividend yield make the fund a buy. JMBS - Overview and Analysis Strategy and Portfolio JMBS focuses on high-quality agency MBS, with smaller allocations to other types of MBS. Weights are as follows: JMBS As can be seen above, JMBS is a leveraged fund, with a somewhat elevated 35.4% leverage. Leverage comes from the fund's use of TBA MBS contracts, basically MBS futures. As is the case with most derivatives, these contracts are generally leveraged, as an investor can easily enter into many high-value contracts with only a small amount of collateral. In most cases, leverage results in increased income, absolute returns, risks, and drawdowns. I'm not confident that this is the case for JMBS, as the accounting on these contracts is complicated, somewhat unclear, and not always reflective of the, let's say, expected performance of an investment. Sometimes the leverage gets hedged out too. JMBS's performance is quite close to that of its benchmark, the iShares MBS ETF ( MBB ), so the leverage does not seem to have resulted in a material increase to its risk or volatility. I'm not expecting an increase moving forward either. Data by YCharts JMBS's active management could result in outperformance for the fund, contingent on effective active management. Risks are higher too, as active management could always be ineffective. I wouldn't expect significant changes in performance due to these issues for JMBS, as agency mortgages are extremely liquid, well-known products, so opportunities for alpha are limited. Risk and Volatility JMBS focuses on quality agency MBS, almost entirely AA. JMBS As agency MBS are ultimately backed by the U.S. Federal Government, credit risk is close to zero. JMBS does have a tiny amount of credit risk, higher than treasu...